CGT Industry Upgrade Series - Beijing New Nest Innovation Center Event Highlights Key Players and Strategic Insights
Yeasen
Tool Enzyme Raw Materials and Diagnostic Product R&D, Manufacturer
VectorBuilder
Gene Delivery Technology Developer
Life Biosciences
Experimental Animal Research Service Provider
Legend Capital
Early-stage venture capital and growth-stage private equity investment institutions
Event Information
On-site View of the New Nest Innovation Center:
Event Scale: 50 people/session
Long-press to scan and register
Highlights
Event Agenda
Fu Rui | Head of the Stem Cell Biology Department, Beijing Tuojie
Wang Yu | Chairman, Darwin Cell Biology
Wang Lijun | CEO, Xingcheng Biotechnology
Guosheng Tan | Key Account Director, Yeasen
Yu Xiaoyu | LePure BioService, R&D Director of CGT
Bai Xinyan | Quality Director, T&L Biotechnology
Liu Bin | Chief Operating Officer, Shenyuan Biologics
Zhu Jing | Head of Clinical Research, Kunling Pharma
Qi Ye | CEO of Evolution Medical
Zhao Xueqiang | Co-founder, Huaxia Yingtai
Wang Yu | Chairman, Darwin Cell Biology
Xie Xingwang | Founder, Kerui Biotech
Chen Xi | General Manager, Zhongyin Technology
Zhang Yang | Director, Healthcare Industry Group, CITIC Securities
Zou Xi | Investment Director, Legend Capital (Moderator)
Guest Introduction
Liu Xiao
Vice President of Business and Marketing, Hangzhou Xingcheng Biotechnology Co., Ltd.
Vice Chairman of the MAH Special Committee, China Pharmaceutical Enterprise Management Association
Liu Xiao, Ph.D. in Strategy from the University of Montpellier (France); EMBA from Nankai University; M.Sc. in Biology from the University of Manchester; postgraduate studies in Finance at the University of Hong Kong; currently pursuing an M.Sc. in Psychology at Arizona State University (USA). Industry Professor at UCMT; Honorary Director of GDA. Senior Engineer in Measurement, Testing, and Instrumentation across China. Thesis Supervisor for Doctoral programs in Health Management, DBA, and MBA, as well as Master’s programs at the University of Montpellier (France). Distinguished Lecturer for workshops at the Business School of the University of Hong Kong and the Business School of Nankai University. Lecturer for the Advanced Leadership Training Program in Biopharmaceuticals at Peking University Health Science Center; Guest Lecturer at Yihong Business School. Vice Chairman of the MAH Special Committee under the China Pharmaceutical Enterprise Management Association; Chief Researcher at the Life Sciences Enterprise Research Center of E-Drug Manager; Special Researcher at the China Biopharmaceutical Infrastructure Alliance. Planner and Host of the “ChatCGT” column.
Formerly served as Head of Marketing for Greater China at Danaher Biotechnology Group, and held positions including Asia-Pacific Marketing Director, Greater China Marketing Director, Consumables Sales Manager, Business Development Manager, and Product Manager at companies such as Cytiva, GE Life Sciences, PerkinElmer, and Thermo Fisher Scientific.
Wang Lijun
CEO of Hangzhou Xingcheng Biotechnology Co., Ltd.
Lijun Wang boasts over 20 years of comprehensive experience in the biopharmaceutical industry, with nearly 17 years dedicated to gene therapy, viral vector process development, and cGMP manufacturing. As an innovative leader in AAV production process development, he specializes in large-scale cell culture and viral vector purification, and is well-versed in analytical methods. He possesses extensive GMP manufacturing experience with AAV, lentivirus, adenovirus, and oncolytic herpes simplex virus (oHSV), along with a thorough understanding of CMC regulations. He has participated in the design of multiple cGMP production facilities and has successfully led and delivered numerous clinical batches of viral vectors. Additionally, he brings rich team management expertise. His previous employers include AGTC, Brammer Bio, and Encoded Therapeutics.
Gao Jinquan
Life Biosciences, Deputy General Manager and General Manager of the Large Animal Model Development Department
Gao Jinquan graduated from the Institute of Laboratory Animal Science, Chinese Academy of Medical Sciences. He specializes in animal surgery, disease model construction, and pharmacodynamic evaluation. He has successfully established various large-animal disease models, with particular expertise in developing non-human primate (NHP) models of neurological disorders, including Parkinson’s disease, amyotrophic lateral sclerosis (ALS), Alzheimer’s disease, spinal cord injury, and stroke. He has provided model development and pharmacodynamic assessment services to numerous CNS drug R&D enterprises. Possessing excellent surgical skills and proficiency in animal experimental techniques, he is well-versed in animal imaging modalities such as B-mode ultrasound, CT, PET-CT, and MRI. He also holds specialized expertise in stereotactic injection into the macaque brain and is proficient in techniques including superovulation, oocyte retrieval, embryo transfer, and cesarean section in macaques. He has participated in multiple national major special projects and disease model R&D initiatives.
Zhou Qihao
Yeasen Vice President
Zhou Qihao joined Yeasen in 2013, advancing from a frontline sales representative to the company’s Vice President of Marketing. He possesses extensive practical experience in business operations and keen industry insights.
Yeasen specializes in the research, development, and manufacturing of upstream raw materials for the biotechnology industry, with applications in life sciences research, drug and vaccine development, and in vitro diagnostics. Guided by its mission to create value for customers and make the world healthier and happier, Yeasen is committed to becoming a leader in the life sciences tools industry.
Kang Wei
Vice President of Strategic Consulting, Austar
Kang Wei has over 28 years of experience in the biopharmaceutical and pharmaceutical industries, having served as a Senior Expert, Subject Matter Expert (SME), and Management Representative at Novo Nordisk Engineering. As an expert in international biopharmaceutical engineering and consulting, he is responsible for early-stage consulting, engineering design, project management, and quality validation for biopharmaceutical and pharmaceutical projects, bringing extensive project experience and profound industry insights. His consulting clients and projects include the Bill & Melinda Gates Foundation, Novo Nordisk, GSK, Novozymes, Boehringer Ingelheim, SANOFI, and WuXi Biologics. Currently serving as Vice President of Austar Group, he focuses on consulting, design, project management, and validation for pharmaceutical engineering projects. Collaborating with an international team of pharmaceutical experts, he provides specialized technical consulting to domestic and global clients in areas such as vaccines, monoclonal antibodies, Advanced Therapy Medicinal Products (ATMPs), and Antibody-Drug Conjugates (ADCs), ensuring compliance with standards from regulatory bodies including the FDA, EMA, WHO, and NMPA. Selected international organizations and speaking engagements:
1. In 2015, at the IBC Life Sciences Biologics Development and Production (BDP) conference in Huntington Beach, California, USA, the presentation was titled “Building China’s Biotechnology Manufacturing Capabilities”
2. 2016 ISPE BioProcess Development Conference, Presentation Title – “Considerations for Biopharmaceutical Facilities from an Engineering Perspective”
3. 2017, ISPE BioForum, Presentation Title – “Best Practices for Biopharmaceutical Project Execution”
4. 2018, ISPE/CIPM Forum, Presentation Title – “Bridging Global Biologics to Local Projects”
5. 2019 ISPE Conference on “Innovative Technologies and Concepts for Biotechnology Facilities,” Presentation Title: “GMP Trends and Expectations for Cell Therapy Facilities”
6. 2020, ISPE/CIPM Forum, Presentation Title – “Case Sharing: Efficient and Compliant Biopharmaceutical Facilities”
Yu Xiaoyu
LePure BioService CGT R&D Director
Yu Xiaoyu has over 10 years of experience in the biopharmaceutical and life sciences industries. From 2012 to 2018, she worked at Hisun Pharmaceutical, where she was responsible for media development, R&D of novel monoclonal antibody drugs, and cell line development. She is well-versed in key upstream biopharmaceutical technologies and possesses in-depth knowledge and extensive experience in critical areas such as cell culture, cell line development, and media development. In 2018, she joined KSBio as a founding team member, leading the R&D of media and cell line products. Currently, she serves as the R&D Director of BioService CGT at LePure Biotechnology, spearheading the development of commercial HEK293 cell lines, culture media, and virus production-related products.
Wang Liyan
Founder and Chairman of Beijing T&L Biotechnology Co., Ltd.
Wang Liyan holds a Master’s degree in Immunology from the Academy of Military Medical Sciences and a Ph.D. in Biology from Johannes Gutenberg University Mainz, Germany. She serves as a committee member of the Cell Research and Therapy Professional Committee under the Chinese Research Hospital Association. With deep expertise in the biopharmaceutical sector, she specializes in the research, development, and manufacturing of upstream raw materials and reagents for cell and gene therapy (CGT). In 2011, she founded Beijing T&L Biotechnology Co.,Ltd., leading her team to establish technical platforms for recombinant protein development, immunomagnetic bead development, and serum-free culture media development, resulting in over one hundred developed products. To date, the company has become an industry-leading provider of comprehensive solutions for key CGT raw materials and reagents. It has been recognized as a National High-Tech Enterprise and a Beijing “Specialized, Refined, Differential, and Innovative” SME, with multiple technological breakthrough projects receiving support from the Ministry of Science and Technology and the Bureau of Economy and Information Technology.
Li Wenxian
Life Biosciences, Deputy General Manager of the Research Services Department
Li Wenxian, with a major in Biological Education, is currently pursuing an MBA at the University of Chinese Academy of Sciences. She serves as an Entrepreneurship Mentor in Hebei Province and works as a Medical Finite Element Engineer. Previously, she was an Assistant Researcher at the Institute of Biophysics, Chinese Academy of Sciences. She possesses strong capabilities in protocol development and experimental operations, and holds over ten patents for inventions and utility models.
Fu Rui
Head of the Stem Cell Biology Department, Beijing Tuojie
Dr. Fu Rui, who holds a Ph.D. in Physiology, has previously worked at the State Key Laboratory of Stem Cell and Reproductive Biology under the Chinese Academy of Sciences, China Resources Group, and Guodian Pharmaceutical. He has been dedicated to translating stem cell research from fundamental studies into industrial applications. Currently, he is responsible for establishing the stem cell biology platform in Beijing and developing stem cell-based therapeutics.
Bai Xinyan
Beijing T&L Biotechnology Co.,Ltd. Quality Director
Bai Xinyan, Master’s degree holder from Cornell University, with over 4 years of quality management experience at a renowned publicly listed biopharmaceutical company. She has led her team through multiple GMP inspections by regulatory authorities and international clients, successfully obtaining quality system certifications including China GMP, US FDA inspection, EU Qualified Person (QP) certification, and Brazil ANVISA approval.
Zhu Jing
Kunling Medicine, Head of Clinical Research
Zhu Jing, currently Head of the China Regional Clinical Research Team at ClinChoice Kunling, graduated from China Pharmaceutical University.
Nearly 19 years of experience in clinical R&D within China’s CRO industry, with extensive expertise in clinical team management. Well-versed in clinical operations and management models, and possesses substantial experience in liaising with and managing diverse client segments.
With years of in-depth experience in clinical trial operations, I have managed or participated in hundreds of projects, facilitating the successful market launch of multiple products;
Currently responsible for managing a clinical research team of over 500 members (including PM, CO, SSU, ISS, and PMS roles), overseeing the operation of more than 100 projects. The portfolio specializes in innovative drugs across multiple therapeutic areas, including oncology, cardiovascular, hematology, nephrology, gynecology, endocrinology, and rare diseases.
Excels in management models for exploring new fields and products, maintaining close collaborations with numerous biotech companies;
Acute market acumen and pragmatic management style deliver more forward-looking clinical operations services to clients;
Prior to joining ClinChoice, served as the Head of the Clinical Project Management Team at Quintiles IMS; previously held positions at leading domestic CRO companies such as Tigermed.
Qi Ye
CEO of Evolution Medical
Qi Ye, Ph.D. from the Academy for Advanced Interdisciplinary Studies at Peking University, has published papers as first and co-author in journals such as Cell, Nature, and Trends in Cell Biology. He has received honors including Beijing Outstanding Graduate and Peking University Outstanding Doctoral Dissertation. Currently serving as CEO and Project Lead at Evolution Medicine, he primarily explores the development of cross-species genetic engineering drugs based on RNA regulation. His achievements include winning the Grand Prize at the 2023 China International College Students’ Innovation Competition, the Global Grand Prize at the 2023 Golden Panda Innovation and Entrepreneurship Competition, the VB-Link Most Innovative Exploration Award, and recognition as one of VCBeat’s 2023 Annual Translational Innovation Projects.
Zhao Xueqiang
Co-Founder of Huaxia Yingtai
Dr. Xueqiang Zhao holds a Ph.D. in Tumor Immunology from the Chinese Academy of Sciences, completed his postdoctoral fellowship at The University of Texas MD Anderson Cancer Center, serves as a Research Fellow at Tsinghua University, and is recognized as a High-Level Overseas Talent Expert in Beijing. With nearly 20 years of experience in basic and translational research in tumor immunology, he has published over 30 papers in prestigious international journals such as Nature Medicine, filed more than 30 patents related to CAR-T and TCR-T therapies, and led or participated in over 20 major scientific projects funded by the National Natural Science Foundation of China, the Ministry of Science and Technology, and Beijing Municipal Science & Technology Commission in the past five years. In 2018, he co-founded Huaxia Yingtai (Beijing) Biotechnology Co., Ltd. with renowned immunologist Professor Xin Lin. Leveraging its proprietary STAR-T technology platform, the company develops autologous and universal gene-edited T-cell immunotherapy products targeting novel antigens in hematologic malignancies and solid tumors. In September 2022, the company’s first dual-target STAR-T product received implicit clinical trial approval from the National Medical Products Administration (NMPA). In January 2024, its innovative STAR-T product targeting dual epitopes of the LILRB4 nanobody also received implicit clinical trial approval. Several first-in-human exploratory clinical trials are currently underway. The company has completed six rounds of equity financing totaling over RMB 400 million and has secured tens of millions in government project grants.
Zhang Yang
Director, Healthcare Industry Group, CITIC Securities
Zhang Yang holds a Bachelor of Pharmacy from Peking University, a Ph.D. in Chemistry from the Institute of Chemistry, Chinese Academy of Sciences, and a Master’s degree in Finance from the University of International Business and Economics. He is a candidate for think tank expert at CITIC Group and an industry expert in healthcare at its Suzhou Branch. He serves as Director of the Healthcare Industry Group within the Investment Banking Committee of CITIC Securities. Licensed to practice in China, Hong Kong, and the United States, he was recognized with two “New Fortune” Best Analyst awards in 2021 and received a “New Fortune” nomination in a specific category in 2022.
Dr. Zhang Yang joined CITIC Securities in 2014. He completed the RMB 1.18 billion financing for Shanghai Allist Pharmaceutical and the USD 110 million financing for OrbusNeich; he handled the IPO of Chengda Biologics, the first company spun off from a Chinese listed enterprise to list on the STAR Market (the first approved “A-share spin-off to A-share” case in China); he managed STAR Market IPOs for Yuekang Pharmaceutical, Yuandong Biopharma, Trauer Biotechnology, Haisco Pharmaceutical, Jinjiang Electronics, Aerospace Taixin, and Yili Pharmaceutical; he handled the Beijing Stock Exchange IPO for Kangle Weishi; he managed HKEX IPOs for Chengda Biologics, Hope Medicine, CARsgen Therapeutics, Imeik, Bio-Thera Solutions, and Junshintai Pharmaceutical; he handled the NASDAQ IPO for Kewei Biotechnology; he served as joint lead underwriter for Frontier Biotechnologies and 3SBio; he managed refinancing transactions for Hybribio (the first case under the registration-based system) and Tofflon Science & Technology; he advised on China Resources Pharmaceutical’s acquisition of Boya Bio-pharmaceutical, and handled financing for China Resources Bio-pharmaceutical and Lixin Pharmaceutical. He also provided financial advisory services for CARsgen Therapeutics, Xingfu Chemical, Chengyi Pharmaceutical, Cyagen Biosciences, and Shenda Endoscopy. The cumulative amount of funds raised exceeded RMB 23.2 billion.
Inventor of the ZCBI (Zhongguancun Life Science Park CITIC Securities Bioeconomy IPO Index).
Zou Xi
Legend Capital, Investment Director
Zou Xi joined Legend Capital in 2018 and currently serves as Investment Director of the healthcare fund at Legend Capital.
Ms. Zou Xi has six years of experience in the biopharmaceutical industry and six years of investment experience in the broader health sector. She previously served as Vice President of Investment at CSC Financial Capital and as Strategy Manager in the Strategy and Business Development Department at Pfizer China.
Representative investment projects include GenScript ProBio, Hanbang Technology, ClinPharm, DiMai BioScience, Docreate Pharma, Promab Biotechnologies, and Gebio. Key sectors of focus include upstream pharmaceutical services/equipment/consumables suppliers, antibody drugs and their derivatives (bispecific antibodies, ADCs, etc.), radiopharmaceuticals, protein degradation, and synthetic biology.
Ms. Zou Xi holds a Bachelor’s degree from the College of Life Sciences at Beijing Normal University and a Master’s degree in International Business Administration from the School of Economics and Management at Tsinghua University.
*The above speakers are listed in agenda order, not by rank.
Company Profile
Hangzhou Xingcheng Biotechnology Co., Ltd.
Yeasen
LePure Biotech
Austar Group
VectorBuilder
Beijing T&L Biotechnology Co.,Ltd.
Life Biosciences
Legend Capital
Beijing New Nest Innovation Center
VCBeat Pharma